News | Stem Cell Therapies | January 17, 2018

Secant Introduces First Synthetic Regenerative Cardiovascular Graft for CABG

Artificial blood vessels offer replacement to harvesting patient’s veins for coronary bypass grafts

Secant Introduces First Synthetic Regenerative Cardiovascular Graft for CABG

January 17, 2018 — Secant Group, in partnership with its sister company SanaVita Medical, announced new technology to advance cardiovascular regenerative medicine with the development of a synthetic, small-bore vessel that encourages endogenous regeneration and new vessel formation. The technology is based on the company’s textile forming capabilities that can produce a hollow lumen construct infused with Secant’s proprietary Regenerez bioresorbable polymer technology. The new small-bore vessel supports the regeneration of new vascular tissue structures without the need for cell seeding or biologic growth promoters.

In situ vascular regeneration, along with the elastomeric and immunomodulatory properties of the synthetic vessel, could solve the problems of vascular harvesting and the non-resorbable synthetic graft compliance mismatching seen with the current technology available for surgeons today. These regenerative grafts will offer new benefits for coronary artery bypass surgery, peripheral vascular disease and renal disease treatments.

Secant has produced small-bore grafts with lumen diameters down to 500 μm, closely matching the range of human vessels. Jeff Robertson, president of Secant Group, explained that by combining Secant’s textile manufacturing and biomaterials capability, this small-bore graft would provide similar compliance as native vasculature, enabling a seamless connection between graft and vessel.

Devices that currently dominate the cardiovascular graft replacement market have numerous limitations including compliance mismatch, low patency rates, calcification, a risk of infection and lack of tissue regeneration capability. The Secant small-bore graft addresses many of these limitations. Early pre-clinical studies have confirmed that Regenerez grafts are non-thrombogenic, did not show occlusion and provide excellent suturability. Secant is continuing the development of small-bore grafts in collaboration with a leading heart and vascular research university. The company is currently looking for medical device partners to progress the technology through clinical trials and commercialization.

For more information: www.secant.com

 


Related Content

News | Stem Cell Therapies

November 19, 2021 — Stem cell therapy helped to reduce the number of heart attacks, strokes and death among people with ...

Home November 19, 2021
Home
News | Stem Cell Therapies

October 28, 2021 – The first patient has been treated in a new trial using stem cell therapy to treat chronic myocardial ...

Home October 28, 2021
Home
Videos | Stem Cell Therapies

Mechanical engineering Professor Nathan Sniadecki, associate chair for research and infrastructure, mechanical ...

Home October 04, 2021
Home
Feature | Stem Cell Therapies | By Simon H. Stertzer, M.D.

Heart failure remains an unheralded global pandemic, costing society billions of dollars each year.[1,2] Projections ...

Home May 11, 2021
Home
Feature | Stem Cell Therapies | By Andy Freeberg

The University of Washington (UW) in Seattle has developed engineered heart tissue that beats. Though minuscule, the ...

Home February 25, 2021
Home
News | Stem Cell Therapies

August 22, 2019 — Renovacor Inc, a preclinical-stage biopharmaceutical company, announced the successful completion of ...

Home August 22, 2019
Home
News | Stem Cell Therapies

May 20, 2019 – Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that stem cells derived from ...

Home May 20, 2019
Home
News | Stem Cell Therapies

April 19, 2019 — Aziyo Biologics Inc. announced the publication of results from its landmark RECON study in the Journal ...

Home April 19, 2019
Home
News | Stem Cell Therapies

March 4, 2019 — The U.S. Food and Drug Administration (FDA) recently finalized two guidance documents regarding ...

Home March 04, 2019
Home
News | Stem Cell Therapies

February 1, 2019 — A team of Rutgers scientists have taken an important step toward the goal of making diseased hearts ...

Home February 01, 2019
Home
Subscribe Now